Literature DB >> 10323263

Interferon-alpha elevates pulmonary blood pressure in sheep--the role of thromboxane cascade.

M Hanaoka1, K Kubo, T Hayano, T Koizumi, T Kobayashi.   

Abstract

We tested the effect of interferon-alpha on lung function to examine whether interferon-alpha causes some pathophysiological change in the lung. We prepared awake sheep with chronic lung lymph fistula, and measured the pulmonary hemodynamics, lung fluid balance and concentrations of prostanoid products. At 1 h after intravenous interferon-alpha administration (18 x 10(6) I.U.), pulmonary arterial pressure and pulmonary vascular resistance were significantly increased compared to the baseline values. The levels of thromboxane B2 in both plasma and lung lymph were increased concomitant with early elevation on pulmonary arterial pressure. In addition, OKY-046 [sodium-3[4-(1-imidazolylmethyl)phenyl]-2-propenoic acid] (10 mg kg(-1)), a selective thromboxane synthase inhibitor, significantly prevented the interferon-alpha-induced pulmonary hypertension and thromboxane B2 production. While no evidence of increased pulmonary vascular leakage was observed. These findings suggest that a single infusion of interferon-alpha stimulates a thromboxane cascade and causes transient pulmonary hypertension. However, interferon-alpha itself or increased thromboxane A2 might not affect the pulmonary vascular permeability in sheep.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323263     DOI: 10.1016/s0014-2999(99)00107-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis.

Authors:  Emma Gibbons; S Promislow; Ross A Davies; George Chandy; Duncan J Stewart; Contreras-Dominguez Vladamir; Carolyn Pugliese; Rosemary Dunne; Lisa M Mielniczuk
Journal:  Can Respir J       Date:  2015-06-17       Impact factor: 2.409

2.  Interferon alpha: A rare cause of persistent pulmonary hypertension of newborn.

Authors:  Hardeep Kaur; Harish Sethi; Gaurav Mahajan
Journal:  Med J Armed Forces India       Date:  2018-02-14

3.  Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection.

Authors:  Rohit B Sangal; Lynn E Taylor; Fizza Gillani; Athena Poppas; James R Klinger; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2014-12

Review 4.  Drug-induced pulmonary arterial hypertension: a review.

Authors:  Lohit Garg; Ghulam Akbar; Sahil Agrawal; Manyoo Agarwal; Leila Khaddour; Rishin Handa; Aakash Garg; Mahek Shah; Brijesh Patel; Bhavinkumar D Dalal
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

5.  Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C.

Authors:  Sonu Dhillon; Anshul Kaker; Aneil Dosanjh; Deepa Japra; David H Vanthiel
Journal:  Dig Dis Sci       Date:  2010-04-22       Impact factor: 3.199

Review 6.  Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.

Authors:  Angélica Ortiz; Serge Y Fuchs
Journal:  Cytokine       Date:  2016-01-25       Impact factor: 3.861

7.  Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report.

Authors:  Nicoline Jochmann; Felix Kiecker; Adrian C Borges; Maja A Hofmann; Stephan Eddicks; Wolfram Sterry; Gert Baumann; Uwe Trefzer
Journal:  Cardiovasc Ultrasound       Date:  2005-09-02       Impact factor: 2.062

Review 8.  Hematological disorders and pulmonary hypertension.

Authors:  Rajamma Mathew; Jing Huang; Joseph M Wu; John T Fallon; Michael H Gewitz
Journal:  World J Cardiol       Date:  2016-12-26

9.  Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.

Authors:  Vincenzo Dattola; Lilla Bonanno; Antonino Naro; Antonino Chillura; Anna Lisa Logiudice; Edoardo Sessa; Fausto Famà; Angelo Quartarone; Rocco Salvatore Calabrò; Silvia Marino; Margherita Russo
Journal:  Biomed Res Int       Date:  2017-09-13       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.